KirkleyCare

Book Now
Book Now

Category: Health and Wellness

  • The Goal Changes as You Age

    Longevity • Recovery • Performance • Healthy Aging

    Stop Treating Recovery Days Like Days Off

    Longevity requires a different way of thinking: some days are designed to create stress and adaptation, while others are designed to help your body absorb that work.

    Most people understand the value of exercise. Fewer people build an intentional system around recovery.

    But as we age, the ability to recover increasingly determines how much productive stress we can continue to tolerate.

    The Goal Changes as You Age

    When you’re young, you can get away with a lot.

    You can sleep poorly, train too often, skip mobility work, eat inconsistently, and still wake up ready to do it again.

    Eventually the margins become smaller.

    Muscles recover more slowly. Connective tissue does not tolerate repeated overload as easily. Sleep becomes increasingly valuable. Stress accumulates. Small injuries linger. And poor habits that once produced very little consequence begin showing up in performance, body composition, mood, energy, and resilience.

    That doesn’t mean aging requires doing less.

    It means we should become more intelligent about how we alternate stress and recovery.

    Longevity is not about avoiding stress. It is about developing the capacity to recover from stress well enough to keep adapting.

    Start Thinking in Two Types of Days

    Instead of expecting every day to look the same, think of your week as alternating between two broad categories:

    Active Days

    These are days where the goal is to challenge the system.

    • Resistance training
    • Higher-intensity cardiovascular work
    • Sprinting or intervals
    • Sports
    • Long hikes
    • Challenging physical work
    • Progressive overload
    • Skill development

    Recovery Days

    These are days where the goal is to restore capacity.

    • Walking
    • Mobility work
    • Stretching
    • Easy cycling
    • Zone 1 or light aerobic movement
    • Breathwork
    • Sauna or heat exposure
    • Massage or soft-tissue work
    • Extra sleep
    • Hydration and nutrition

    What Is an Active Day Really For?

    Exercise is a form of controlled stress.

    When you lift weights, you challenge muscle and connective tissue. When you run intervals, you challenge cardiovascular and metabolic systems. When you practice a sport, you challenge coordination, reaction time, power, and nervous-system function.

    That challenge sends a message:

    “This environment requires me to become more capable.”

    That is where adaptation begins.

    But exercise itself is not the adaptation. It is the stimulus for adaptation.

    Recovery Is Where the Work Gets Converted Into Capacity

    This distinction matters.

    Training creates the demand.

    Recovery gives the body the opportunity to respond to that demand.

    Muscle proteins are rebuilt. Glycogen is restored. connective tissue remodels. Nervous-system fatigue decreases. Inflammatory signaling resolves. Hormonal and autonomic systems move back toward balance.

    If you repeatedly create stress without adequately restoring capacity, eventually the training stimulus stops being productive.

    You are no longer adapting to stress.

    You are simply accumulating it.

    Active days create the reason to adapt. Recovery days create the conditions that allow adaptation.

    Recovery Days Still Need a Routine

    One of the biggest mistakes is interpreting “recovery” as doing absolutely nothing.

    A good recovery day still contains deliberate habits.

    Walk

    Low-intensity movement supports circulation without adding much additional physiological stress.

    Move Through Range

    Mobility work keeps joints moving and lets you address stiffness before it becomes limitation.

    Sleep More

    Sleep is one of the most powerful recovery tools available and should be treated like part of the training plan.

    Eat to Rebuild

    Protein, micronutrients, carbohydrates, and adequate calories provide the raw materials needed for recovery.

    Downshift Stress

    Breathing, prayer, time outside, relaxation, or quiet activity can help reduce the cumulative stress load.

    Restore Hydration

    Fluids and electrolytes matter for circulation, muscle function, and overall recovery.

    Recovery Days Should Feel Different

    There is a tendency to make every workout moderate.

    Not truly hard. Not truly easy.

    That can create a strange middle ground where the body experiences enough stress to require recovery but not enough stimulus to produce maximal adaptation.

    A better strategy is often to allow hard days to actually be hard and easy days to actually be easy.

    That separation gives you room to perform with greater intensity when intensity matters.

    Longevity Is About Preserving Capacity

    The goal of training in your 40s, 50s, 60s, and beyond should not simply be to prove how much discomfort you can tolerate.

    The bigger goal is to preserve:

    strength, muscle mass, cardiovascular capacity, balance, coordination, mobility, bone density, metabolic health, and confidence in your body.

    You want to remain capable enough that life itself stays easy.

    Carrying groceries should be easy. Getting off the floor should be easy. Traveling should be easy. Playing with grandchildren should be easy. Hiking should remain possible.

    That requires training.

    But it also requires remaining healthy enough to keep training.

    The Positive Feedback Loop

    This is where the strategy becomes powerful.

    When recovery improves, your active days improve.

    Better Recovery
    →
    Better Training
    →
    Greater Adaptation
    →
    More Capacity
    →
    Better Recovery

    You sleep better.

    You enter your next workout with more energy.

    You can train harder.

    Your body receives a stronger adaptive stimulus.

    You gain more strength and conditioning.

    Increased fitness improves your ability to tolerate future stress.

    And because you tolerate stress better, you recover more effectively.

    That creates a positive feedback loop.

    Recovery improves performance. Better performance improves fitness. Better fitness improves resilience. Resilience improves your ability to recover.

    The Opposite Loop Exists Too

    Poor recovery can snowball in the other direction.

    Poor sleep leads to poor training.

    Poor training increases frustration.

    Fatigue reduces movement during the rest of the day.

    Pain changes movement patterns.

    Chronic stress increases.

    Motivation falls.

    Fitness declines.

    As capacity falls, activities that used to be easy require more physiological effort.

    Now recovery becomes even harder.

    The direction of the loop matters.

    Build the Week—Not Just the Workout

    Instead of waking up each day and asking, “What workout should I do?” ask a bigger question:

    “What does my body need today to make the entire week productive?”

    Some days the answer may be heavy resistance training.

    Another day may be intervals.

    Another may be a long walk, mobility work, protein, water, and an early bedtime.

    All three can be equally important.

    Recovery Is Not the Opposite of Progress

    Active days and recovery days are two parts of the same system.

    Training challenges your biology. Recovery allows that biology to adapt.

    As we age, the people who continue performing well may not always be the people willing to push the hardest.

    They may be the people who become best at deciding when to push and when to restore.

    Train with purpose. Recover with purpose. Repeat for decades.

  • What If Weight Loss Is Only the Beginning?

    Metabolic Health • Heart • Brain • Cancer • Longevity

    What If Weight Loss Is Only the Beginning?

    GLP-1 medications are usually discussed as weight-loss drugs. The more interesting question may be what happens downstream when obesity, glucose, cardiovascular risk, kidney stress, and other metabolic problems improve at the same time.

    We do not yet have twenty or thirty years of randomized data for modern obesity-dose GLP-1 therapy.

    But we are beginning to accumulate something potentially more important than a smaller number on the scale: actual disease-outcome data.

    Drew Kirkley, MSN, APRN, AGNP-C KirkleyCare Metabolic & Personalized Wellness

    For years, the conversation around GLP-1 medications sounded something like this:

    How much weight did they lose?

    That is an important outcome.

    But it may eventually turn out to be one of the least interesting parts of the story.

    Excess adiposity does not exist in isolation.

    It interacts with glucose regulation, insulin resistance, blood pressure, inflammation, liver health, kidney health, sleep apnea, cardiovascular disease, mobility, and multiple cancers.

    So when a therapy improves several parts of that biological environment simultaneously, it raises a much bigger question:

    What diseases might become less common twenty years downstream?

    Heart attacks?

    Strokes?

    Kidney failure?

    Dementia?

    Certain cancers?

    We do not have definitive answers to all of those questions.

    But the signals are becoming difficult to ignore.

    First: “GLP-1” Is Not One Drug

    Class effects should not automatically be assumed for every molecule

    GLP-1 receptor agonists include medications such as semaglutide, liraglutide, and dulaglutide.

    Tirzepatide is slightly different because it activates both the GIP and GLP-1 receptors.

    These medications share overlapping physiology, but they are not interchangeable research compounds.

    A cardiovascular outcome demonstrated with semaglutide should not automatically be assigned to every GLP-1-based medication.

    Follow the Specific Evidence

    Throughout this article, “GLP-1 medications” describes the broader therapeutic category, but specific outcomes should be attributed to the specific molecule and population actually studied.

    Not Every Benefit Has the Same Level of Evidence

    This is probably the most important distinction in the entire conversation
    Established

    Cardiovascular Outcomes

    Randomized outcome trials demonstrate reductions in major cardiovascular events with specific GLP-1 therapies in selected high-risk populations.

    Supported

    Kidney Outcomes

    Semaglutide has reduced clinically meaningful kidney outcomes in randomized patients with type 2 diabetes and chronic kidney disease.

    Emerging

    Dementia & Cancer

    Large observational studies are generating intriguing signals, but they cannot establish prevention or causality.

    Still Unknown

    Multi-Decade Effects

    We do not yet know the full benefit-risk profile of using modern obesity-dose therapy continuously across decades.

    Why Would a Weight-Loss Medication Affect More Than Weight?

    Because body weight is connected to an entire metabolic environment

    A GLP-1 medication does not simply make a scale number smaller.

    In many patients, treatment is accompanied by changes in several biological variables at the same time.

    Body Fat

    Lower adiposity changes the endocrine and metabolic environment created by excess fat tissue.

    Glucose

    GLP-1-based therapies can improve glycemic control and reduce progression toward diabetes in appropriate populations.

    Blood Pressure

    Weight reduction and metabolic improvement can influence cardiovascular workload and blood pressure.

    Inflammation

    Weight loss and improved metabolic health can reduce several inflammatory signals associated with obesity.

    Kidney Stress

    Specific GLP-1 therapies now have randomized evidence of kidney protection in selected high-risk patients.

    Liver Health

    Reducing excess adiposity and metabolic dysfunction can improve metabolic liver disease in many patients.

    Mobility

    Less excess body weight may reduce mechanical load and make physical activity easier for some people.

    Cardiovascular Risk

    This is no longer theoretical for semaglutide in certain high-risk populations.

    Less Excess Adiposity
    →
    Better Metabolic Environment
    →
    Less Organ Stress
    →
    Fewer Downstream Events?

    The Question Mark Matters

    Improving a risk factor does not automatically prove that every disease associated with that risk factor will be prevented.

    Ultimately, we need outcome data.

    For Cardiovascular Disease, We Already Have Outcome Data

    This is where the conversation moved beyond weight loss

    The SELECT trial enrolled more than 17,600 adults with overweight or obesity and established cardiovascular disease—but without diabetes.

    Participants received semaglutide 2.4 mg or placebo in addition to standard care.

    SELECT Trial

    Randomized, double-blind cardiovascular outcome trial
    17,604 participants
    6.5% major cardiovascular event with semaglutide
    8.0% major cardiovascular event with placebo

    The primary outcome—cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke—was reduced by about 20% on a relative basis.

    This was meaningful enough that the FDA subsequently approved Wegovy to reduce the risk of cardiovascular death, heart attack, and stroke in adults with established cardiovascular disease and overweight or obesity.

    For cardiovascular disease, we are no longer asking whether the biomarkers look better.

    We have fewer actual cardiovascular events.

    What About Stroke Specifically?

    The signal is encouraging—but individual trials need to be interpreted carefully

    Stroke is part of the cardiovascular composite used in several major GLP-1 outcome trials.

    In SUSTAIN-6, which enrolled patients with type 2 diabetes at high cardiovascular risk, nonfatal stroke occurred in 1.6% of semaglutide-treated patients compared with 2.7% receiving placebo.

    That corresponded to a hazard ratio of 0.61.

    SELECT was somewhat different.

    The overall cardiovascular composite clearly improved, but the individual nonfatal-stroke result by itself was not statistically significant.

    Don’t Turn a Composite Benefit Into an Unsupported Claim

    Semaglutide has strong cardiovascular-outcome evidence. There is also supportive evidence for stroke reduction, particularly across high-risk diabetes studies.

    But we should not tell every patient that a GLP-1 medication has been proven to prevent their future stroke.

    Then the Kidney Data Arrived

    Another example of benefits extending beyond weight and glucose

    The FLOW trial randomized 3,533 patients with type 2 diabetes and chronic kidney disease to semaglutide or placebo.

    FLOW Trial

    Randomized kidney-outcome trial
    24% lower relative risk of the primary kidney outcome
    18% lower major cardiovascular-event risk
    20% lower all-cause mortality risk

    That does not mean every person taking semaglutide receives the same kidney benefit.

    FLOW involved a very specific high-risk population.

    But again, the important point is that we are measuring real clinical events, not simply watching the scale move.

    Biomarkers Are Clues. Outcomes Are the Goal.

    This distinction becomes critical when we talk about dementia and cancer

    The Tempting Assumption

    Weight Improves
    Glucose Improves
    Inflammation Improves
    Risk Factors Improve
    Disease Must Improve

    That last step is where we can get into trouble.

    A biomarker may correlate with disease risk.

    It may even sit directly inside the biological pathway.

    But changing a biomarker does not always change the clinical outcome we care about.

    Better biology gives us a reason to investigate. It does not give us permission to skip the outcome trial.

    Could GLP-1 Therapy Reduce Dementia Risk?

    This may be one of the most interesting unanswered questions

    Dementia does not develop overnight.

    The biological processes leading toward cognitive decline may evolve over many years.

    Cardiovascular disease, diabetes, hypertension, obesity, kidney disease, and metabolic dysfunction can all interact with brain health.

    That makes the idea of modifying metabolic risk decades earlier biologically interesting.

    Metabolic Pathway

    Improving diabetes, obesity, and vascular risk could indirectly improve the environment in which the aging brain has to function.

    Neurologic Interest

    GLP-1 signaling has also generated research interest involving neuroinflammation, neuronal metabolism, and neurodegenerative biology.

    The Missing Piece

    We still need randomized prevention trials showing fewer people actually develop dementia.

    The Real-World Dementia Signal Is Interesting

    Association is not causation—but the size of the databases gets attention

    A 2024 target-trial-emulation study examined more than one million eligible patients with type 2 diabetes without a previous Alzheimer’s diagnosis.

    Semaglutide users had lower rates of first-time Alzheimer’s disease diagnosis compared with several other diabetes treatments.

    Depending on the comparator, the reported hazard ratios ranged from roughly 0.33 against insulin to 0.59 compared with other GLP-1 receptor agonists.

    A subsequent 2025 real-world analysis examining broader Alzheimer’s-related dementias also found lower dementia incidence among semaglutide users compared with insulin, metformin, and older GLP-1 therapies.

    Very Interesting. Still Not Proof.

    Electronic-health-record studies attempt to adjust for differences between groups, but they cannot eliminate every form of confounding.

    People prescribed semaglutide may differ from comparison groups in ways that influence dementia risk.

    Then Came an Important Reality Check

    Semaglutide did not slow established Alzheimer’s disease in Phase 3

    Novo Nordisk tested oral semaglutide in two large randomized Phase 3 trials known as EVOKE and EVOKE+.

    Together, the studies enrolled 3,808 adults with mild cognitive impairment or mild dementia due to Alzheimer’s disease.

    After two years, semaglutide did not significantly slow clinical disease progression compared with placebo.

    What makes the result particularly interesting is that Alzheimer’s-related biomarkers did improve.

    The clinical outcome did not.

    Biomarkers Changed

    Semaglutide produced changes in Alzheimer’s-related biological markers during the trials.

    Disease Progression Did Not

    Those biological changes did not translate into a statistically significant slowing of clinical progression.

    This may be one of the best modern examples of why biomarkers are not the same thing as outcomes.

    But Prevention and Treatment Are Not the Same Question

    Failure to slow established Alzheimer’s disease does not answer whether earlier metabolic treatment could change future dementia risk

    This distinction matters.

    Giving semaglutide to someone who already has measurable Alzheimer’s disease asks:

    Can this medication slow an existing neurodegenerative process?

    The Phase 3 answer so far is: not convincingly.

    But using metabolic therapy years earlier asks a different question:

    Could reducing obesity, diabetes, vascular disease, kidney disease, and other metabolic risks reduce the probability of dementia developing later?

    We do not yet have a randomized answer to that question.

    This Is a Hypothesis Worth Testing

    The observational signal is intriguing. The known metabolic and cardiovascular benefits make biological sense.

    But “may reduce future dementia risk” and “prevents Alzheimer’s disease” are two very different claims.

    Then There Is Cancer

    Another area where the early data are provocative—but not definitive

    Excess adiposity is associated with increased risk for multiple cancers.

    That immediately raises a reasonable question:

    If a therapy produces substantial, sustained reductions in excess body fat and improves the metabolic environment around that fat, could certain obesity-associated cancers become less common?

    Researchers are beginning to look.

    2024

    1.65 Million Patients With T2D

    GLP-1 receptor agonists were associated with lower risk of 10 of 13 obesity-associated cancers compared with insulin.

    2025

    Adults With Obesity

    A matched cohort of more than 86,000 adults found lower overall cancer incidence among GLP-1 users compared with nonusers.

    2026

    Obesity Without Diabetes

    A target-trial-emulation study found lower short-term incidence of obesity-associated cancers among GLP-1 users compared with people receiving diet or exercise counseling alone.

    The Comparator Changes the Cancer Story

    This is why observational research has to be interpreted carefully

    In the 2024 study of more than 1.65 million patients with type 2 diabetes, GLP-1 receptor agonists were associated with lower rates of ten obesity-associated cancers compared with insulin.

    These included colorectal, endometrial, ovarian, liver, pancreatic, gallbladder, esophageal, kidney cancers, meningioma, and multiple myeloma.

    That sounds dramatic.

    But there is an important detail:

    When GLP-1 users were compared with metformin instead of insulin, the investigators did not find statistically significant reductions in those cancers.

    Comparator Matters

    People who require insulin often have longer-standing or more advanced diabetes than people treated with other medications.

    Observational studies can adjust for known differences, but some differences may remain.

    A 2025 Obesity Cohort Added Another Signal

    This study moved beyond diabetes alone

    GLP-1 Use and Cancer Risk in Adults With Obesity

    Retrospective matched cohort • JAMA Oncology • 2025
    86,632 matched adults
    0.83 hazard ratio for overall cancer incidence
    17% lower relative overall cancer incidence

    Lower incidence was specifically reported for endometrial cancer, ovarian cancer, and meningioma.

    There was also a possible signal toward increased kidney cancer that deserves further study.

    Again: association, not proof of prevention.

    The 2026 Data Became Even More Interesting

    Researchers specifically studied obesity without diabetes

    A 2026 target-trial-emulation study evaluated obese adults without diabetes.

    After matching, the analysis included more than 161,000 people.

    GLP-1 use was associated with a lower short-term incidence of a composite of 13 obesity-associated cancers compared with diet or exercise counseling.

    2026 Annals of Oncology Analysis

    Obesity without diabetes • Median follow-up approximately 2 years
    161,798 propensity-matched participants
    0.59 hazard ratio for obesity-associated cancer composite
    ~2 Years median follow-up

    Two Years Is Not Long-Term Cancer Prevention

    Many cancers develop over years or decades.

    The study itself was designed to evaluate short-term cancer incidence, not prove lifelong cancer prevention.

    If Cancer Risk Eventually Falls, Why Might That Happen?

    We should not automatically assume the medication is directly “anti-cancer”

    There are several possibilities.

    Some could be indirect.

    Substantial fat loss changes the metabolic environment.

    Insulin signaling can improve.

    Glucose exposure may improve.

    Liver fat may improve.

    Chronic inflammatory signaling associated with obesity may change.

    Physical activity may become easier.

    Those effects could theoretically influence cancer risk without the medication directly killing a single cancer cell.

    Sometimes preventing disease may be less about attacking the disease and more about changing the environment in which the disease develops.

    We Also Have to Discuss the Cancer Warning

    The cancer conversation cannot include only the reassuring data

    Semaglutide products carry an FDA boxed warning regarding thyroid C-cell tumors.

    In rodent studies, semaglutide caused thyroid C-cell tumors.

    Whether that finding translates to humans remains unknown.

    For that reason, Wegovy is contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

    Reassuring Signal

    Large human observational datasets have not produced a simple signal showing broad increases in overall cancer incidence.

    Remaining Uncertainty

    Multi-decade cancer surveillance is still unavailable for modern high-dose obesity treatment.

    “May Reduce Some Cancers” Does Not Mean “No Cancer Risk”

    Benefits and risks need to be evaluated separately rather than turning either side into a blanket conclusion.

    What Do We Mean When We Say “We Don’t Know the Long-Term Effects”?

    Long-term is relative

    GLP-1 biology is not brand new.

    Earlier GLP-1 receptor agonists have been used clinically for years, and semaglutide was first approved in the United States in 2017.

    What we do not have is a randomized trial showing what happens when millions of relatively young adults use high-potency obesity therapy continuously for twenty or thirty years.

    Months GI tolerance, appetite, weight response
    Years Cardiovascular and kidney outcome data
    Decades Dementia, cancer, lifelong body composition
    Lifetime Full benefit-risk balance still unknown

    Unknown Does Not Mean Unsafe

    It means the observation period has not yet been long enough to answer every question.

    The same uncertainty also applies to potential benefits that may require decades to become visible.

    The Long Game Still Has Tradeoffs

    Better metabolic health does not make a medication biologically free

    Gastrointestinal Effects

    Nausea, vomiting, diarrhea, constipation, and intolerance can limit therapy in some people.

    Gallbladder Disease

    Gallstone and gallbladder risks are part of the established safety discussion.

    Pancreatitis

    Acute pancreatitis remains an important labeled clinical warning.

    Lean Tissue

    Significant weight loss can include lean-mass loss, making protein intake and resistance training important considerations.

    Nutrition

    Profound appetite suppression can make inadequate protein, calories, or micronutrient intake easier to overlook.

    Retinopathy

    Rapid glycemic improvement deserves consideration in patients with diabetes and preexisting retinopathy.

    Thyroid Warning

    Rodent C-cell tumor findings remain part of FDA labeling even though their relevance to humans is uncertain.

    Long-Term Unknowns

    Multi-decade exposure data for modern obesity treatment simply do not exist yet.

    But “We Don’t Have 30-Year Data” Cuts Both Ways

    Doing nothing also has long-term consequences

    This is a part of the risk conversation that is often forgotten.

    Imagine someone is 45 years old with obesity, hypertension, insulin resistance, sleep apnea, fatty liver, and rising glucose.

    We could say:

    “We don’t know what thirty years of GLP-1 therapy will do.”

    True.

    But we should immediately ask the other question:

    What are thirty more years of obesity, hypertension, insulin resistance, sleep apnea, and metabolic dysfunction likely to do?

    The decision is rarely medication versus zero risk. It is one risk profile versus another.

    Maybe We Should Stop Thinking of These as “Weight-Loss Drugs”

    Weight loss may be one visible expression of a much larger metabolic intervention

    If someone loses 20% of their body weight but we only celebrate the number on the scale, we may be missing the real victory.

    What happened to their blood pressure?

    Their glucose?

    Their liver?

    Their kidneys?

    Their cardiovascular risk?

    Their sleep apnea?

    Their mobility?

    Their ability to exercise?

    Their risk profile twenty years from now?

    Health Is a Systems Outcome

    The most meaningful effect of a metabolic medication may not be the first biomarker that changes.

    It may be the disease that never develops.

    We Should Be Excited Without Getting Ahead of the Science

    There is plenty here to be optimistic about without pretending the unanswered questions are settled

    Too Far

    “GLP-1 medications prevent Alzheimer’s disease and cancer.”

    We do not have evidence strong enough to make that statement.

    Scientifically Defensible

    “GLP-1 therapies improve several established disease risk factors, have proven cardiovascular and kidney benefits in selected populations, and are generating emerging signals for reduced dementia and cancer incidence that deserve further study.”

    This Could Be a Much Bigger Public-Health Story Than Weight Loss

    The real payoff may happen years after the scale stops moving

    Imagine millions of people entering middle age with:

    Less visceral fat.

    Better glucose control.

    Lower cardiovascular risk.

    Less kidney disease.

    Better mobility.

    Improved sleep apnea.

    More ability to exercise.

    Better metabolic health.

    It would be surprising if none of those changes influenced the diseases that appear decades later.

    The magnitude of that influence remains unknown.

    But that may ultimately be the most important research question surrounding this class of medications.

    What If the Scale Is Only the First Biomarker?

    The visible effect of GLP-1 therapy is weight loss. The more important effect may eventually be a different metabolic environment maintained over years—and fewer cardiovascular, renal, neurologic, and possibly oncologic events downstream.

    Weight loss is the beginning of the question. Healthspan is the outcome we actually care about.

    The Right Question Is Not “Are GLP-1s Good or Bad?”

    That’s too simple for a therapy affecting this many biological systems

    The better questions are:

    Who benefits?

    What risks does that person already have?

    What risks does the medication introduce?

    What risks does improving obesity and metabolic health remove?

    How much muscle are we preserving?

    Are nutrition and resistance training part of the strategy?

    What happens after five years?

    Ten?

    Twenty?

    The most important benefit of a medication may be the event that never happens.

    We already know that fewer cardiovascular events can happen in the right patients.

    We already know kidney outcomes can improve in the right population.

    We have intriguing—but still unproven—signals involving dementia and cancer.

    And we have decades of questions still left to answer.

    Follow the Outcomes, Not Just the Scale

    Weight matters. But cardiovascular disease, kidney failure, stroke, dementia, cancer, mobility, strength, and independence matter more.

    The ultimate goal isn’t weight loss. It’s better health for more years.

    Is Metabolic Therapy the Right Lever for You?

    A personalized wellness consultation can look at your goals, body composition, metabolic health, cardiovascular risk, medications, nutrition, muscle preservation, and the available options to determine what makes sense for your individual situation.

    Book a Wellness Consultation

    About the Author

    Better health happens when the whole system works together

    Drew Kirkley, MSN, APRN, AGNP-C

    Adult-Gerontology Nurse Practitioner • University Nursing Professor • Founder of KirkleyCare

    Drew Kirkley’s approach to personalized wellness focuses on helping people understand how metabolic health, muscle, cardiovascular risk, sleep, nutrition, hormones, medications, and other biological systems interact—and identifying practical, evidence-informed levers that may help them achieve their individual health goals.

    Selected Scientific References

    Randomized trials, regulatory information, and emerging observational research discussed in this article
    Lincoff AM, et al. New England Journal of Medicine. 2023.
    SELECT randomized trial of semaglutide and cardiovascular outcomes in adults with overweight or obesity, established cardiovascular disease, and no diabetes.
    View SELECT on PubMed →
    U.S. Food & Drug Administration. 2024.
    FDA approval of Wegovy to reduce cardiovascular death, heart attack, and stroke in adults with established cardiovascular disease and overweight or obesity.
    View FDA Announcement →
    Marso SP, et al. New England Journal of Medicine. 2016.
    SUSTAIN-6 cardiovascular outcome trial in patients with type 2 diabetes at high cardiovascular risk, including nonfatal stroke outcomes.
    View SUSTAIN-6 →
    Perkovic V, et al. New England Journal of Medicine. 2024.
    FLOW randomized trial examining semaglutide and major kidney, cardiovascular, and mortality outcomes in type 2 diabetes with chronic kidney disease.
    View FLOW →
    Wang W, et al. Alzheimer’s & Dementia. 2024.
    Target-trial-emulation study examining associations between semaglutide use and first-time Alzheimer’s disease diagnosis in patients with type 2 diabetes.
    View Study →
    Wang W, et al. Journal of Alzheimer’s Disease. 2025.
    Large real-world target-trial-emulation study examining semaglutide and Alzheimer’s disease-related dementias.
    View Study →
    Novo Nordisk. EVOKE / EVOKE+ Phase 3 Results. 2025.
    Two randomized Phase 3 studies found that oral semaglutide did not significantly slow clinical progression in early symptomatic Alzheimer’s disease despite changes in Alzheimer’s-related biomarkers.
    View Phase 3 Results →
    Wang L, et al. JAMA Network Open. 2024.
    Cohort of more than 1.65 million patients with type 2 diabetes examining GLP-1 receptor agonists and 13 obesity-associated cancers.
    View Study →
    Dai H, et al. JAMA Oncology. 2025.
    Retrospective matched cohort examining GLP-1 receptor agonist use and cancer incidence among adults with overweight or obesity.
    View Study →
    Hsu AHC, et al. Annals of Oncology. 2026.
    Target-trial-emulation analysis examining GLP-1 receptor agonist use and short-term obesity-associated cancer incidence among obese adults without diabetes.
    View Study →
    Current Wegovy Prescribing Information.
    Current FDA-approved labeling, including cardiovascular indication, warnings, precautions, and boxed warning regarding thyroid C-cell tumors.
    View Current Label →
    Educational Disclaimer: This article is intended for general education and commentary and does not provide individualized medical advice. Cardiovascular and kidney benefits described above apply to specific medications and patient populations studied in randomized clinical trials and should not automatically be generalized to every GLP-1-based therapy or patient. Current evidence does not establish GLP-1 receptor agonists as medications for the prevention of Alzheimer’s disease or cancer. Dementia and cancer findings discussed above are primarily observational and may be affected by residual confounding. Semaglutide did not significantly slow clinical progression in the EVOKE and EVOKE+ Phase 3 trials involving patients with early symptomatic Alzheimer’s disease. GLP-1 medications also have established adverse effects, contraindications, and unanswered long-term questions. Medication decisions should be individualized according to medical history, expected benefit, potential risk, body composition, nutritional status, concurrent medications, and patient goals.

  • The Energy Budget: Why Your Body Can’t Prioritize Everything at Once

    Energy • Stress • Adaptation • Recovery • Allostasis

    The Energy Budget: Why Your Body Can’t Prioritize Everything at Once

    Your body is constantly spending energy to keep you alive, moving, thinking, healing, adapting, and responding to the world around you.

    Exercise costs energy. Immunity costs energy. Digestion costs energy. Thermoregulation costs energy. Tissue repair costs energy. Reproduction costs energy. Even maintaining basic cellular function costs energy.

    The question isn’t whether your body has energy. The more interesting question is: what is demanding that energy right now?

    Drew Kirkley, MSN, APRN, AGNP-C KirkleyCare Personalized Wellness

    Imagine having a checking account with ten different bills due at the same time.

    You can pay all of them easily when the account is full.

    But what happens when the bills keep getting bigger while the deposits get smaller?

    Eventually priorities have to change.

    Your biology faces a similar problem.

    Every moment, trillions of cells are performing work.

    Maintaining ion gradients. Moving molecules. Contracting muscle. producing proteins. repairing damage. generating heat. transmitting nerve signals. fighting pathogens.

    All of it has an energetic cost.

    Your body has a budget. Stress has a price.

    First: Your Body Does Not Literally Divide ATP Into Pie Slices

    The energy-budget model is a teaching tool—not literal cellular accounting

    There is no central energy bank somewhere in your abdomen deciding that the brain gets 20%, your immune system gets 15%, and your muscles get whatever is left.

    ATP is produced and consumed locally throughout the body.

    Different tissues use different fuels and have very different metabolic demands.

    Blood flow, oxygen delivery, nutrient availability, hormones, autonomic signals, mitochondrial activity, and cellular signaling all help determine what happens where.

    But the budget analogy is still useful because biological resources are not unlimited.

    When demand changes, physiology changes with it.

    Think Dynamic Allocation—not Fixed Percentages

    The body’s priorities can shift according to illness, food availability, exercise, injury, temperature, psychological stress, sleep, pregnancy, growth, and countless other signals.

    Think of Your Available Capacity Like a Pie

    The slices are constantly changing

    Adequately Fueled + Recovering

    Demand exists, but the system has enough capacity to respond and recover.
    Brain
    Movement
    Repair
    Reproduction
    Stress Response
    Immune Function
    Thermoregulation

    High Demand + Poor Recovery

    Injury, illness, heavy training, inadequate food, poor sleep, or chronic stress can change the biological workload.
    Stress Response ↑
    Immune Demand ↑
    Repair Demand ↑
    Brain
    Movement
    Reproduction ↓
    Thermoregulation

    Conceptual illustration only. Slice sizes do not represent measured physiological percentages or a literal distribution of ATP.

    Almost Everything Your Body Does Has an Energetic Cost

    Some costs are obvious. Others are happening quietly in the background.

    Exercise

    Muscle contraction rapidly increases ATP turnover. Training also creates a later requirement for repair, remodeling, and adaptation.

    Immune Activation

    Activated immune cells proliferate, move, manufacture signaling molecules, and substantially change their metabolism.

    Stress Response

    Autonomic and endocrine responses help mobilize resources so the body can respond to a perceived challenge.

    Tissue Repair

    Healing requires immune coordination, protein synthesis, cellular migration, extracellular-matrix remodeling, and energy.

    Reproduction

    Reproductive function is sensitive to nutritional and energetic status, particularly when energy availability becomes inadequate.

    Digestion

    Breaking down, absorbing, processing, transporting, and storing nutrients requires energy of its own.

    Thermoregulation

    Shivering, sweating, vascular changes, and heat production help defend core temperature under environmental stress.

    Brain Function

    Neurons continually require energy to maintain ion gradients, transmit signals, recycle neurotransmitters, and sustain network activity.

    This Is Where Allostasis Comes In

    Staying stable often requires constant change

    We often talk about homeostasis as keeping the body’s internal environment stable.

    But the body does not maintain stability by remaining static.

    Heart rate changes.

    Blood flow changes.

    Hormones change.

    Glucose availability changes.

    Immune activity changes.

    Metabolism changes.

    The term allostasis describes the process of maintaining stability through those adjustments.

    Challenge
    →
    Detect
    →
    Mobilize Resources
    →
    Respond
    →
    Recover
    →
    Adapt

    Stress Is Not Automatically Bad

    A healthy system is supposed to respond to stress. The ability to mount a response and then return toward baseline is part of physiological resilience.

    Exercise Proves That Stress Can Be Good

    The goal isn’t to eliminate stress. It’s to recover from it.

    Exercise temporarily disrupts homeostasis.

    ATP turnover rises.

    Glycogen is used.

    Calcium flux changes.

    Mechanical tension increases.

    Cellular stress signals rise.

    That sounds terrible if we stop the story there.

    But after the workout, biological remodeling begins.

    Proteins are synthesized. Mitochondrial machinery adapts. Muscle remodels. Neural coordination improves.

    With an appropriate training dose and enough recovery, the system can return stronger and more capable than it was before.

    Exercise Is a Withdrawal

    You intentionally spend energy, challenge tissue, disturb homeostasis, and create a biological problem that needs to be solved.

    Adaptation Is the Deposit

    When recovery and nutrition are adequate, the response to that challenge can increase future capacity.

    Exercise doesn’t make you stronger while you’re doing it. Recovery is where the adaptation is purchased.

    The Problem Is When the Bill Never Stops Arriving

    Acute adaptation and chronic overload are not the same physiology

    Acute Stress

    Train. Recover. Adapt.

    Fight an infection. Resolve it. Return toward baseline.

    Handle a difficult week. Sleep. Recover.

    Chronic Load

    Hard training + calorie restriction + poor sleep + psychological stress + injury + another hard training session.

    The biological challenge continues before the previous challenge has fully resolved.

    Stress Isn’t the Enemy. Unpaid Stress Is.

    Problems become more likely when demand repeatedly exceeds the system’s ability to recover and adapt.

    Your Immune System Is Expensive

    Fighting an infection requires more than antibodies

    Resting immune cells can rapidly change their metabolism when they become activated.

    They may need to proliferate.

    Travel through tissue.

    Produce cytokines.

    Build antibodies and other proteins.

    Destroy pathogens.

    Coordinate repair.

    Those functions require ATP and raw materials.

    Fever adds another energetic expense because raising body temperature increases metabolic demand.

    Ever wonder why being sick makes you want to lie on the couch? Reducing activity may help redirect resources toward the response your body is trying to mount.

    Reproduction Gives Us One of the Clearest Examples of Prioritization

    When energy availability becomes inadequate, biology can change priorities

    Researchers have studied this extensively in athletes.

    When food intake does not adequately support both exercise and normal physiological function, a state known as low energy availability can occur.

    In women, inadequate energy availability can disrupt reproductive signaling and menstrual function.

    Bone metabolism can also be affected.

    Related endocrine changes have been described in male athletes as well, although the physiology and susceptibility are not identical.

    Survival-Critical Functions

    Maintaining temperature, cellular integrity, circulation, and essential organ function cannot simply be turned off.

    Growth & Bone

    Chronic inadequate energy availability can alter endocrine signals involved in growth and bone remodeling.

    Reproduction

    Reproductive physiology is particularly sensitive to severe or sustained energy deficiency.

    This Is Not “The Body Shuts Off Hormones Whenever You’re Stressed”

    Hormonal symptoms have many possible causes. The point is that energy availability is one biologically meaningful signal the endocrine system can respond to.

    Your Brain Is Already an Expensive Organ

    The brain consumes substantial energy even when you are sitting still

    Roughly

    ~20%

    The adult brain represents only a small fraction of total body weight but accounts for roughly one-fifth of whole-body oxygen and glucose utilization at rest.

    Neurons continuously spend energy maintaining electrochemical gradients and signaling networks.

    But there is an important myth worth correcting:

    Thinking really hard does not suddenly double your total daily calorie expenditure.

    The brain’s baseline energy requirement is already substantial.

    Mental stress can still matter enormously through sleep, autonomic activity, endocrine signaling, appetite, behavior, and other systems without needing to dramatically increase the number of calories burned by thinking.

    Even Eating Costs Energy

    Calories have to be processed before the body can use them

    Digestion is not passive.

    Food has to be mechanically and chemically broken down.

    Nutrients must be absorbed.

    Transported.

    Converted.

    Stored.

    Or used.

    This increase in energy expenditure following food intake is known as the thermic effect of food or diet-induced thermogenesis.

    For a typical mixed diet, it contributes roughly 5–15% of daily energy expenditure, although it varies with the amount and composition of food.

    Food Is Both Fuel and Work

    Your digestive system has to spend some energy before the rest of the body can access the energy contained in food.

    Temperature Is Another Non-Negotiable Expense

    Your enzymes don’t care that you wanted to save the energy for something else

    Human physiology operates within a relatively narrow range of core temperatures.

    In the cold, the body may constrict blood vessels, shiver, and increase heat production.

    In heat, circulation shifts toward the skin and water is used for evaporative cooling through sweat.

    Those adaptations consume resources.

    Biology doesn’t care about your priorities. Maintaining core temperature gets paid first.

    Chronic Demand Can Show Up Somewhere You Weren’t Expecting

    The symptom may appear downstream from the original stressor

    This is where the energy-budget concept becomes useful clinically.

    Someone may believe their problem is “energy.”

    But maybe they are sleeping five hours.

    Training six days per week.

    Eating in a large calorie deficit.

    Recovering from an injury.

    Working twelve-hour shifts.

    And dealing with significant psychological stress.

    That isn’t one problem.

    That’s a biological workload.

    Fatigue
    Poor Recovery
    Performance Decline
    Sleep Problems
    Mood Changes
    Low Libido
    Menstrual Changes
    Increased Injury Risk

    These Symptoms Are Not Specific to “Energy Depletion”

    Fatigue, poor libido, sleep disturbance, menstrual changes, impaired exercise tolerance, mood changes, and slow recovery can have important medical causes.

    The energy-budget model is a framework for asking better questions—not a diagnosis.

    Your Recovery Account Has Deposits and Withdrawals

    The goal isn’t to eliminate withdrawals. It’s to maintain enough capacity to pay them.

    You don’t become resilient by never making withdrawals. You become resilient by building an account capable of paying them.

    Recovery Is Not Doing Nothing

    Recovery is active biology

    Rest can look passive from the outside.

    Internally, the body may be doing anything but resting.

    Proteins are being synthesized.

    Glycogen is being restored.

    Damaged structures are being remodeled.

    Immune signals are being resolved.

    Nervous-system activity is changing.

    Mitochondrial proteins are being produced.

    1

    Sleep

    Protect time for neurologic, metabolic, and physical recovery.

    2

    Nutrition

    Provide energy, amino acids, micronutrients, and substrates needed for rebuilding.

    3

    Appropriate Load

    Enough challenge to stimulate adaptation without endlessly outrunning recovery.

    4

    Time

    Biological remodeling occurs on its own timeline—not ours.

    This Is Why “More” Isn’t Always Better

    More interventions can create more demand without fixing the bottleneck

    More training.

    More fasting.

    More supplements.

    More stimulants.

    More cold exposure.

    More sauna.

    More medications.

    More peptides.

    More optimization.

    At some point, more inputs can simply become more biological noise.

    The Question Should Be: What Does the System Need?

    Sometimes the right lever adds a useful signal.

    Sometimes the right lever is removing unnecessary demand.

    This Is Why Personalized Wellness Starts With the Whole System

    Don’t treat the symptom before understanding the workload

    If someone tells me, “I have no energy,” I don’t immediately think:

    What can we give them for energy?

    I want to know:

    How are they sleeping?

    Are they eating enough?

    Are they metabolically healthy?

    Are they anemic?

    Are they hypothyroid?

    Are medications contributing?

    Are they training too hard?

    Are they recovering from an illness?

    Is there untreated sleep apnea?

    What is their psychological workload?

    What is their physical workload?

    In other words:

    Where is the energy going—and why?

    Maybe Fatigue Isn’t Always an Energy-Production Problem

    Sometimes production is only one side of the equation

    Mitochondrial health matters.

    Cellular energy production matters.

    But increasing production is not the only possible answer.

    Imagine a company that can’t pay its bills.

    One solution is to increase revenue.

    Another is to figure out why expenses are out of control.

    Energy Is About Production AND Demand

    Better mitochondrial function can increase biological capacity. But health also depends on the demands being placed on that capacity—and whether the system has enough recovery to adapt.

    Don’t only ask how to make more energy. Ask what is spending it.

    The Goal Isn’t to Live a Stress-Free Life

    A system that never gets challenged never gets the signal to become stronger

    Lift weights.

    Challenge your cardiovascular system.

    Learn difficult things.

    Work toward meaningful goals.

    Build resilience.

    Stress your biology appropriately.

    But then give it what it needs to respond.

    Food.

    Protein.

    Sleep.

    Recovery.

    Time.

    The goal isn’t less stress. The goal is greater capacity.

    That is a very different way of thinking about wellness.

    We don’t simply try to eliminate every biological challenge.

    We build a system capable of handling more without breaking down.

    Build a Bigger Biological Budget

    Improve your mitochondrial capacity. Build muscle. Improve cardiovascular fitness. Sleep. Eat enough quality food. Address disease. Recover from training. Reduce unnecessary chronic stressors.

    Build the system. Then give it meaningful work to do.

    Where Is Your Biggest Bottleneck?

    A personalized wellness consultation looks at your goals, symptoms, sleep, metabolic health, activity, nutrition, medications, recovery, and other demands to identify which factors may deserve the most attention.

    Book a Wellness Consultation

    About the Author

    Better health happens when the whole system works together

    Drew Kirkley, MSN, APRN, AGNP-C

    Adult-Gerontology Nurse Practitioner • University Nursing Professor • Founder of KirkleyCare

    Drew Kirkley’s approach to personalized wellness focuses on helping people understand how mitochondrial energy, metabolism, muscle, stress, sleep, hormones, nutrition, recovery, and other biological systems interact—and identifying practical, evidence-informed levers that may help them achieve their individual health goals.

    Selected Scientific References

    Research supporting the energy-allocation, allostasis, and adaptation concepts discussed above
    Bobba-Alves N, et al. 2023.
    The energetic cost of allostasis and allostatic load. A systems-level framework examining how biological adaptation uses energetic resources and how persistent demand may contribute to physiological strain.
    View Research →
    Williams NI, et al. Sports Medicine. 2019.
    Review of energy availability, reproductive function, bone health, and biological energy allocation in female and male athletes.
    View Research →
    Areta JL, et al. 2021.
    Review of low energy availability and its endocrine, metabolic, reproductive, bone, and skeletal-muscle effects.
    View Research →
    Pearce EL, et al. 2016.
    Immunometabolism research describing the metabolic reprogramming required for immune-cell activation, proliferation, and effector function.
    View Research →
    Straub RH, et al.
    Review of brain-immune interactions and the energetic demands of immune activation, fever, and resource allocation during illness.
    View Research →
    Westerterp KR. Nutrition & Metabolism. 2004.
    Review of diet-induced thermogenesis and the energetic costs of nutrient digestion, absorption, processing, and storage.
    View Research →
    Mergenthaler P, et al. Trends in Neurosciences. 2013.
    Review of glucose metabolism and the substantial energetic requirements of normal brain function.
    View Research →
    Hill RW, et al. 2013.
    Research examining the substantial energetic requirements associated with maintaining body temperature.
    View Research →
    Brook MS, et al. Journal of Applied Physiology. 2017.
    Review describing post-exercise skeletal-muscle protein synthesis, recovery, remodeling, and adaptation.
    View Research →
    Memme JM, et al. 2018.
    Review of the molecular response connecting acute exercise, cellular energy stress, signaling, and mitochondrial biogenesis.
    View Research →
    Educational Disclaimer: The “energy budget” and “energy pie” concepts used in this article are teaching models intended to illustrate changing biological demands. The body does not distribute ATP according to fixed percentages, and the diagrams above should not be interpreted as quantitative physiological measurements. Symptoms including fatigue, poor exercise tolerance, low libido, menstrual changes, sleep disturbance, mood changes, or impaired recovery can have many medical causes and should not automatically be attributed to stress, mitochondrial dysfunction, or low energy availability. This article is intended for general health education and does not replace individualized medical evaluation, diagnosis, or treatment.

  • Cholesterol Is Essential. Atherosclerosis Is the Problem.

    Cholesterol • Metabolism • Cardiovascular Risk • Personalized Medicine

    Cholesterol Is Essential. Atherosclerosis Is the Problem.

    Cholesterol helps build your hormones, cell membranes, vitamin D, and bile acids. So how did one of the most important molecules in human biology become something we’re simply trying to make lower?

    Maybe the better question isn’t, “How low can we make the cholesterol number?”

    Maybe it’s: “What is this person’s actual cardiovascular risk—and what is driving it?”

    Drew Kirkley, MSN, APRN, AGNP-C KirkleyCare Personalized Wellness

    Let’s start with something that often gets lost in the cholesterol conversation:

    Your body needs cholesterol.

    Not a little bit.

    Cholesterol is built into cell membranes throughout the body. It is used to make steroid hormones. It helps produce bile acids. It is part of the pathway used to produce vitamin D.

    Cortisol starts downstream from cholesterol.

    Aldosterone starts downstream from cholesterol.

    Testosterone. Estrogen. Progesterone.

    All connected to cholesterol biology.

    Cholesterol isn’t a toxin your body accidentally forgot to get rid of.

    It is essential human biology.

    Cholesterol Sits at the Center of Important Biology

    A simplified look at what the body uses cholesterol to build
    Cholesterol Is a Building Block
    Simplified physiological overview
    Major biological uses of cholesterol Diagram showing cholesterol as a central molecule contributing to cell membranes, steroid hormones, vitamin D and bile acids. CHOLESTEROL Essential Building Block Steroid Hormones Cortisol • Aldosterone Testosterone • Estrogen • Progesterone Cell Membranes Structure • Fluidity Cellular Signaling Bile Acids Fat Digestion Nutrient Absorption Vitamin D Pathway Bone • Calcium • Cellular Function

    Cell Membranes

    Cholesterol contributes to membrane structure, stability, fluidity, and cellular signaling.

    Hormones

    Cholesterol is the precursor for adrenal and sex steroid hormones.

    Vitamin D

    Cholesterol-derived molecules participate in the pathway that ultimately produces vitamin D.

    Bile Acids

    Cholesterol is converted into bile acids that help digest and absorb dietary fat.

    But Here’s the Important Distinction

    Cholesterol inside your biology and cholesterol traveling through your bloodstream are related—but not identical concepts

    Cholesterol does not dissolve freely in blood.

    It has to be transported inside particles called lipoproteins.

    LDL is one of those transport systems.

    And each atherogenic particle carries a structural protein called apolipoprotein B—or ApoB.

    Think of Cholesterol as Cargo

    Cholesterol is something the body needs to move between tissues.

    Measuring LDL-C tells us roughly how much cholesterol is being carried inside LDL particles.

    Think of ApoB Particles as Trucks

    ApoB provides another way of estimating the number of atherogenic particles circulating through the bloodstream.

    Two people can have similar LDL-C while carrying that cholesterol in different numbers of particles.

    Essential Does Not Mean “More Is Always Better”

    The fact that cholesterol is essential to human physiology does not make elevated concentrations of circulating atherogenic lipoproteins harmless.

    Genetic studies, epidemiology, and randomized clinical trials provide strong evidence that prolonged exposure to ApoB-containing lipoproteins contributes causally to atherosclerosis.

    So Is It the Cholesterol—or the Environment?

    The most accurate answer is: both matter

    This is where the cholesterol debate often becomes unnecessarily binary.

    One side says:

    “LDL is the entire problem.”

    The other says:

    “LDL doesn’t matter. It’s only inflammation and metabolic health.”

    Human biology is more complicated than either statement.

    The number and duration of exposure to atherogenic particles matters.

    But so does the biological environment those particles are traveling through.

    Blood Pressure
    Smoking
    Diabetes
    Insulin Resistance
    Triglycerides
    Kidney Disease
    Inflammatory Conditions
    Family History
    Atherosclerotic Risk ≠ LDL-C Alone Particle exposure + time + metabolic environment + blood pressure + genetics + smoking + other risk factors

    Context Doesn’t Make ApoB Disappear

    A metabolically healthy person with elevated ApoB may have a different absolute risk than a smoker with diabetes, hypertension, kidney disease, and the same ApoB.

    But better metabolic health does not make long-term exposure to atherogenic particles irrelevant.

    What Does a Standard Lipid Panel Actually Tell You?

    Useful information—but still only part of the cardiovascular picture
    Standard Test Total Cholesterol

    The cholesterol contained across several circulating lipoprotein classes.

    Standard Test LDL-C

    The amount of cholesterol carried within LDL particles—not necessarily the particle number itself.

    Standard Test HDL-C

    Cholesterol carried within HDL particles. It is a risk marker but should not be interpreted as a simple protective antidote to LDL.

    Standard Test Triglycerides

    Circulating fats influenced by metabolic health, genetics, alcohol, diet, and recent food intake.

    A lipid panel is valuable. It is not a complete cardiovascular autobiography.

    Your Lipid Panel Is a Snapshot in Time

    But that doesn’t mean the snapshot is meaningless

    Blood biomarkers are dynamic.

    Diet changes. Weight changes. Alcohol intake changes. Exercise changes. Illness changes. Medications change. Metabolic health changes.

    So yes—a lipid panel represents what was happening biologically around the time it was measured.

    What Recent Food Can Change

    Triglycerides are the standard lipid measurement most affected by recent eating.

    A particularly large or high-fat meal can produce a more noticeable post-meal triglyceride response.

    What We Shouldn’t Say

    A meal the night before does not usually make the entire lipid panel meaningless.

    Modern guidelines accept nonfasting lipid testing for many routine cardiovascular-risk assessments.

    In large studies, habitual meals generally caused only modest average changes in total cholesterol and LDL-C.

    Triglycerides changed more.

    ApoB and Lp(a) are much less affected by whether someone recently ate.

    One Result Is a Data Point. Trends Are More Informative.

    An unexpected result can often be repeated under consistent conditions before making a major long-term decision—particularly when the result does not fit the rest of the clinical picture.

    Sometimes the Standard Panel Doesn’t Tell the Whole Story

    The newest guidelines increasingly recognize that cardiovascular risk requires context

    ApoB

    Estimates the total number of circulating atherogenic ApoB-containing particles and can be especially informative when triglycerides, diabetes, or metabolic syndrome create disagreement between LDL-C and particle burden.

    Lipoprotein(a)

    A largely inherited cardiovascular risk factor. Current guidance recommends measuring Lp(a) at least once in adulthood.

    Non-HDL Cholesterol

    Captures cholesterol carried in all ApoB-containing atherogenic lipoproteins, not LDL alone.

    Metabolic Markers

    Glucose regulation, triglycerides, body composition, blood pressure, and diabetes status can substantially alter overall cardiovascular risk.

    Risk Enhancers

    Family history, kidney disease, inflammatory conditions, reproductive history, smoking, and other clinical factors may change how a lipid result should be interpreted.

    Coronary Calcium

    In selected adults where the treatment decision remains uncertain, coronary artery calcium imaging may help clarify whether subclinical coronary atherosclerosis is already present.

    Interestingly, This Is Now Mainstream Cardiology

    The 2026 ACC/AHA dyslipidemia guideline incorporates overall cardiovascular risk, PREVENT risk estimates, ApoB, Lp(a), risk enhancers, and selective coronary calcium testing when making treatment decisions.

    In other words: context matters.

    So Are Statins Really the Answer?

    Sometimes absolutely. Sometimes the decision deserves more context.

    Statins inhibit an enzyme called HMG-CoA reductase in the cholesterol-synthesis pathway.

    The liver responds by increasing LDL receptors on its surface, which helps remove more circulating LDL particles from the blood.

    Statin
    →
    ↓ Hepatic Cholesterol Synthesis
    →
    ↑ LDL Receptors
    →
    ↑ Particle Clearance
    →
    ↓ Circulating LDL-C

    A Statin Does Not Simply “Remove Cholesterol From Your Body”

    Cholesterol metabolism is highly regulated. The major therapeutic effect of statins is to reduce exposure of the arterial system to circulating atherogenic lipoproteins.

    We Should Also Be Honest About Something Else: Statins Work

    Questioning how we prescribe them is different from pretending they have no clinical benefit

    Randomized clinical trials involving very large numbers of people have demonstrated that lowering LDL with statin therapy reduces major cardiovascular events.

    That effect is especially important when someone’s baseline risk is already high.

    Someone who has already had a myocardial infarction, stroke, or established atherosclerotic disease is having a completely different risk-benefit conversation than a healthy younger adult with one mildly abnormal laboratory value.

    Higher Baseline Risk

    When the probability of a cardiovascular event is high, lowering atherogenic lipoprotein exposure can create a meaningful absolute reduction in risk.

    Lower or Uncertain Risk

    When absolute risk is lower or the decision is uncertain, it becomes increasingly important to understand the entire risk profile rather than treating one laboratory value in isolation.

    The question shouldn’t be, “Are statins good or bad?”

    The better question is: what is the expected benefit for this person?

    What About Statin Side Effects?

    They are real—but the internet version and randomized-trial version are not always the same

    Statins are medications.

    Medications can produce adverse effects.

    Muscle symptoms receive the most attention, and some people genuinely experience statin-associated muscle symptoms.

    Statins can also modestly increase diabetes risk in susceptible patients and can produce abnormalities in liver enzymes.

    Severe muscle injury such as rhabdomyolysis is possible but rare.

    Muscle Symptoms

    Real in some people, but blinded trials show the excess caused by statins is considerably smaller than the total number of muscle complaints reported while people happen to be taking them.

    Blood Glucose

    Statins can slightly increase the likelihood of newly diagnosed diabetes, particularly in people already metabolically predisposed.

    Liver Enzymes

    Mild laboratory elevations occur somewhat more frequently with statin therapy. Serious liver injury remains uncommon.

    Cognition

    Large randomized analyses have not demonstrated convincing evidence that statins routinely cause cognitive impairment or dementia.

    A Long Side-Effect List Does Not Tell You the Probability

    A symptom appearing in someone taking a medication is not automatically caused by that medication.

    Large blinded randomized trials are particularly useful because they allow us to compare symptoms against people taking placebo.

    But “Statins Are Safe” Shouldn’t End the Conversation Either

    An intervention should provide enough expected benefit to justify its inconvenience, cost, uncertainty, and potential adverse effects for the individual taking it.

    My Problem Is Not With Lowering LDL

    My problem is pretending one number is the entire patient

    Imagine two patients both have an LDL-C of 155 mg/dL.

    Patient A is physically active, normotensive, nonsmoking, metabolically healthy, with low triglycerides, no diabetes, no chronic kidney disease, reassuring family history, and no evidence of coronary calcification.

    Patient B smokes, has hypertension, diabetes, high triglycerides, chronic kidney disease, elevated ApoB, and a strong family history of premature coronary disease.

    Same LDL-C.

    Very different cardiovascular conversation.

    Treat the risk. Don’t just treat the red number on the laboratory report.

    Cardiovascular Risk Usually Doesn’t Arrive Alone

    Patterns often tell us more than isolated abnormalities

    When someone develops significant metabolic dysfunction, it is often not one biomarker that changes.

    We may see some combination of:

    Higher Triglycerides
    Lower HDL-C
    Higher ApoB
    Higher Glucose
    Higher A1C
    Higher Blood Pressure
    Central Adiposity
    Fatty Liver Risk

    That pattern is telling a bigger biological story than one isolated cholesterol value.

    Biomarkers Are Clues

    They are most useful when they help us understand the physiology occurring underneath them.

    What Would a Personalized Cholesterol Conversation Look Like?

    Start with cardiovascular risk—not medication ideology
    1

    Verify the Pattern

    Review previous lipid results and repeat unexpected values when appropriate.

    2

    Assess Total Risk

    Consider age, blood pressure, smoking, diabetes, kidney health, family history, and other relevant risk factors.

    3

    Clarify When Needed

    ApoB, Lp(a), non-HDL-C, or selective CAC imaging can sometimes add useful information when the decision remains uncertain.

    4

    Choose the Lever

    Nutrition, weight loss, exercise, smoking cessation, blood pressure treatment, statins, or another lipid-lowering strategy may each be appropriate depending on the individual.

    Cholesterol Is a Perfect Example of Why Personalized Medicine Matters

    Both extremes miss something important

    “Cholesterol is bad” is too simple.

    Cholesterol is essential to life.

    “LDL doesn’t matter” is also too simple.

    Long-term exposure to ApoB-containing lipoproteins plays a causal role in atherosclerosis.

    “Everyone with an elevated LDL needs the same treatment” is too simple.

    Absolute risk, age, comorbidities, genetics, metabolic health, existing plaque, patient preferences, and treatment tolerance all matter.

    Don’t Optimize the Lab. Optimize the Person.

    Cholesterol is one component of cardiovascular biology. The goal is not to win an argument about LDL or statins. The goal is to reduce the patient’s lifetime risk of heart attack, stroke, disability, and premature death while preserving overall health.

    Understand the biology. Understand the risk. Then choose the lever.

    Maybe the Better Question Isn’t “Do I Need a Statin?”

    At least not as the first question

    Start with:

    What is my actual cardiovascular risk, what is driving that risk, and which intervention gives me the best risk-to-benefit tradeoff?

    For some people, the answer will absolutely include a statin.

    For others, the immediate priority may be smoking cessation, blood pressure, body composition, exercise, sleep, nutrition, diabetes treatment, or further risk clarification.

    Often it will be several of those things at once.

    That is what happens when we stop treating health as one isolated laboratory value and start looking at the system.

    One Number Is Not a Wellness Strategy

    Use the lipid panel. Respect what it tells you. Understand what it cannot tell you. Then put it into the context of the entire patient.

    The target isn’t cholesterol. The target is cardiovascular risk.

    Want to Better Understand Your Cardiovascular Risk?

    A personalized wellness consultation can review your goals, lipid history, metabolic health, lifestyle, medications, risk factors, and available options so you can have a more informed conversation about what your numbers actually mean.

    Book a Wellness Consultation

    About the Author

    Better decisions begin with understanding the biology

    Drew Kirkley, MSN, APRN, AGNP-C

    Adult-Gerontology Nurse Practitioner • University Nursing Professor • Founder of KirkleyCare

    Drew Kirkley’s approach to personalized wellness focuses on helping people understand how metabolic health, cardiovascular risk, muscle, nutrition, sleep, hormones, medications, and other biological systems interact—and identifying practical, evidence-informed levers that may help them achieve their individual health goals.

    Selected Scientific References

    Research and current clinical guidance supporting this discussion
    Cholesterol Physiology — National Library of Medicine.
    Overview of cholesterol’s roles in cell membranes and its use as a precursor for steroid hormones, vitamin D, and bile acids.
    View on PubMed →
    Ference BA, et al. European Heart Journal. 2017.
    Consensus review of genetic, epidemiologic, Mendelian-randomization, and randomized-trial evidence establishing LDL and ApoB-containing lipoproteins as causal contributors to atherosclerotic cardiovascular disease.
    View on PubMed →
    Boren J, et al. European Heart Journal. 2020.
    Review of the biological mechanisms linking retention of ApoB-containing lipoproteins to the initiation and progression of atherosclerosis.
    View on PubMed →
    2026 ACC/AHA Guideline on the Management of Dyslipidemia.
    Current U.S. recommendations incorporating PREVENT risk calculation, LDL-C and non-HDL-C goals, ApoB, Lp(a), risk enhancers, and selective coronary artery calcium assessment.
    View 2026 Guideline →
    American Heart Association — ApoB.
    Patient and clinician education describing ApoB as a marker of circulating atherogenic particle number.
    View AHA Information →
    Nordestgaard BG, et al. European Heart Journal. 2016.
    Consensus review comparing fasting and nonfasting lipid testing, including typical post-meal changes in triglycerides, LDL-C, ApoB, and Lp(a).
    View Consensus Statement →
    Cholesterol Treatment Trialists’ Collaboration.
    Large randomized-trial meta-analyses demonstrating reduction in major vascular events with statin-mediated LDL lowering.
    View on PubMed →
    Cholesterol Treatment Trialists’ Collaboration. Lancet. 2022.
    Individual-participant meta-analysis examining muscle symptoms in large double-blind randomized statin trials.
    View on PubMed →
    Statin Adverse Effects Meta-Analysis. 2026.
    Large individual-participant analysis of adverse events attributed to statins in double-blind randomized controlled trials.
    View on PubMed →
    Educational Disclaimer: This article is intended for general health education and commentary and does not provide individualized cardiovascular or medication advice. Cholesterol and lipoprotein interpretation depends on age, medical history, existing cardiovascular disease, blood pressure, diabetes, kidney function, smoking, family history, genetics, medications, laboratory trends, and other factors. Statins and other lipid-lowering medications have established cardiovascular benefits in appropriately selected patients and should not be started, stopped, or changed based on this article. Anyone considering a change in prescribed lipid-lowering therapy should discuss their individual risk, expected benefit, potential adverse effects, and alternatives with an appropriate health professional.

  • The Most Underrated Longevity Drug is Muscle

    Longevity • Strength • Metabolism • Independence

    The Most Underrated Longevity Drug Is Muscle

    We spend billions looking for molecules that might help us live longer while ignoring one of the most powerful determinants of how well we function as we age: the tissue attached to our bones.

    Muscle influences glucose metabolism, insulin sensitivity, mitochondrial function, strength, mobility, bone loading, recovery, and our ability to tolerate illness.

    No, muscle is not literally a drug. That is exactly the point.

    Drew Kirkley, MSN, APRN, AGNP-C KirkleyCare Healthy Aging & Personalized Wellness

    If someone invented a medication that could improve strength, glucose handling, physical function, metabolic health, bone loading, and resilience during aging , we would probably call it a breakthrough.

    Fortunately, we already have access to something that influences all of those systems.

    It’s called skeletal muscle.

    Unfortunately, muscle is often treated like a cosmetic accessory.

    Something for athletes. Something for bodybuilders. Something that makes you look better at the beach.

    That’s an incredibly narrow view of what muscle actually does.

    Muscle isn’t decoration. It is metabolic, functional, and physiological infrastructure.

    Muscle Does Far More Than Move Your Skeleton

    It participates in systems that influence how we function throughout life

    Metabolic Health

    Skeletal muscle takes up and stores glucose and plays an important role in whole-body insulin sensitivity.

    Strength & Function

    Muscle generates the force required to stand, walk, climb, carry, balance, and remain physically independent.

    Bone Loading

    Muscular force and appropriately designed resistance exercise provide mechanical signals that help stimulate bone.

    Physiologic Reserve

    Muscle provides functional and amino-acid reserve that becomes particularly important during aging, inactivity, illness, and recovery.

    Strength Is a Health Metric

    Looking muscular and being physically capable are not the same thing

    One of the most important concepts in healthy aging is that muscle size is not the entire story.

    Strength, power, coordination, muscle quality, and the ability to actually use that tissue matter tremendously.

    In the large international PURE study, lower grip strength was associated with greater risk of all-cause mortality, cardiovascular mortality, and cardiovascular disease.

    A handgrip test obviously does not determine how long someone will live.

    But strength appears to tell us something important about the overall health and resilience of the person producing it.

    Muscle Mass

    How much lean tissue do you have?

    This matters—but quantity alone does not tell us how well that tissue functions.

    Muscle Function

    How strong are you? How quickly can you generate force? Can you get off the floor? Carry groceries? Climb stairs?

    Function is ultimately what determines independence.

    The Goal Is Not Just More Muscle

    The goal is muscle you can actually use.

    Muscle Is One of Your Most Important Metabolic Organs

    Every contraction is also a metabolic event

    We tend to think about glucose regulation as a pancreas problem.

    The pancreas absolutely matters.

    But skeletal muscle is also a major destination for glucose.

    Insulin helps move glucose from the bloodstream into muscle cells, where it can be used for energy or stored as glycogen.

    Exercise creates another powerful signal for glucose uptake and improves the way muscle handles fuel.

    Blood Glucose
    →
    Insulin + Muscle Contraction
    →
    Muscle Glucose Uptake
    →
    Energy / Glycogen Storage

    Think of Muscle as Metabolic Capacity

    More importantly than simply having more tissue, having active, insulin-responsive muscle gives the body another place to handle incoming fuel.

    Your Muscles Talk to the Rest of Your Body

    Skeletal muscle is not just mechanical tissue—it also communicates

    When muscle contracts, it releases signaling molecules commonly referred to as myokines.

    Human experiments have demonstrated that contracting skeletal muscle can produce and release interleukin-6 during exercise.

    That discovery helped change the way scientists think about skeletal muscle.

    Muscle is now understood as an active tissue capable of sending signals that interact with other parts of the body.

    Muscle → Metabolism

    Contracting muscle changes glucose uptake, fuel utilization, and metabolic signaling.

    Muscle → Other Tissues

    Myokine signaling provides one pathway through which active muscle may communicate with distant tissues.

    Movement → Systemic Signal

    Exercise is not simply burning calories. It sends biological instructions throughout the body.

    Every workout is more than movement. It is a message to your biology.

    Muscle Is Also a Mitochondrial Organ

    Energy production and physical capacity are deeply connected

    Skeletal muscle contains large numbers of mitochondria because repeated contraction requires enormous amounts of ATP.

    Training gives mitochondria a reason to adapt.

    In research involving older adults, high-intensity exercise increased several markers of skeletal-muscle mitochondrial content.

    Resistance-training studies have also demonstrated improvements in skeletal-muscle oxidative capacity and mitochondrial-related biology.

    Physical Demand
    →
    Cellular Stress Signal
    →
    Adaptation
    →
    Greater Functional Capacity

    Want Healthier Mitochondria? Give Them a Job.

    Supplements and experimental mitochondrial therapies are interesting, but mitochondria also respond powerfully to the physiological demand created by movement and exercise.

    Strong Muscle Helps Create Stronger Infrastructure

    Muscle and bone are mechanically connected

    Bone responds to mechanical loading.

    That load can come from impact, body weight, and the forces muscles generate when they contract against resistance.

    The LIFTMOR randomized trial studied supervised high-intensity resistance and impact training in postmenopausal women with low bone mass.

    After eight months, the high-intensity training group demonstrated better lumbar-spine bone mineral density and improvements across measures of physical function compared with the low-intensity control program.

    Loading Matters

    Bones need an appropriate mechanical reason to stay strong. Muscle helps provide that reason.

    People with osteoporosis or significant medical limitations should use appropriately supervised exercise rather than simply copying a high-intensity research protocol.

    Muscle Is Your Physiologic Savings Account

    You may not appreciate your reserve until life makes a withdrawal

    This may be the part of the muscle conversation that receives the least attention.

    Illness happens. Surgery happens. Injuries happen. Hospitalizations happen.

    And when they do, people often move less while the body is facing increased physiological demands.

    Muscle can be lost surprisingly quickly during periods of inactivity.

    What Can 10 Days of Inactivity Do?

    10 Days Complete Bed Rest in Older Adults

    Experimental bed-rest studies in healthy older adults have demonstrated losses in lean tissue, strength, functional capacity, and skeletal-muscle mitochondrial function over a remarkably short period of inactivity.

    More Reserve

    More strength and functional capacity give you more room to absorb a temporary setback.

    You may lose something during illness or inactivity—but you have more capacity to lose.

    Little Reserve

    When someone begins an illness already weak, sedentary, and under-muscled, even a relatively short period of inactivity can have significant functional consequences.

    Muscle is a reserve account. Build it before life sends you the bill.

    Aging Makes the Muscle Conversation More Important—not Less

    Losing strength should not simply be accepted as an unavoidable lifestyle

    Aging is associated with changes in muscle mass, strength, neuromuscular function, and the anabolic response to nutrition and exercise.

    But age does not eliminate the ability to adapt.

    Resistance-training studies in older adults repeatedly demonstrate that people can improve strength and physical function well beyond middle age.

    One study comparing older and younger adults even found substantial changes in muscle gene-expression patterns after six months of resistance training, along with significant improvement in strength among the older participants.

    Aging Is Not an Argument Against Training

    It is one of the strongest arguments for it.

    The GLP-1 Era Makes Muscle Even More Important

    Weight loss and health improvement are not exactly the same thing

    GLP-1-based medications have changed obesity treatment.

    They can produce substantial reductions in body weight and body fat.

    But whenever body weight falls significantly—whether through medication, diet, bariatric surgery, or other methods—some lean tissue may also be lost.

    That has created understandable concern about muscle during GLP-1-assisted weight loss.

    Oversimplified Version

    “GLP-1 medications destroy muscle.”

    That statement goes beyond the evidence.

    Better Question

    How do we maximize fat loss while preserving as much functional muscle, strength, and physical capacity as possible?

    Recent human research is reassuring.

    A 2026 study examining GLP-1-associated weight loss reported reductions in absolute lean and muscle measures, but did not find evidence of disproportionate muscle loss or worsening muscle function. Relative muscle measures and mobility improved.

    Another prospective semaglutide study found early lean-mass loss but subsequent stabilization, with improvements in handgrip strength during follow-up.

    Don’t Fear Effective Weight Loss. Protect the Infrastructure.

    The goal should not be to avoid losing weight because some lean tissue may be lost.

    The better strategy is to deliberately support muscle with resistance training, sufficient nutrition, adequate protein, and continued assessment of strength and function.

    Building Muscle Requires Both a Signal and Raw Materials

    Training tells the body what to build. Nutrition helps provide what it needs to build it.

    Resistance exercise provides the mechanical signal.

    Protein provides amino acids.

    Recovery gives the adaptation time to occur.

    None of these works particularly well in isolation.

    1

    Resistance Training

    Provide progressive mechanical tension and give the muscle a reason to adapt.

    2

    Protein

    Provide the amino-acid building blocks needed for muscle protein remodeling.

    3

    Energy & Micronutrients

    Extreme under-fueling makes building and preserving lean tissue more difficult.

    4

    Recovery

    Sleep, rest, and appropriate training volume allow adaptation rather than endless breakdown.

    Especially Important During Weight Loss

    When calories fall and weight is dropping rapidly, protecting skeletal muscle deserves intentional attention—not an afterthought.

    Stop Confusing “Lighter” With “Healthier”

    The scale cannot tell you what you are made of

    Someone can weigh less while also being weaker.

    Someone can lose twenty pounds while losing both fat and muscle.

    Someone else can lose less total weight but preserve strength, maintain lean tissue, improve glucose control, and dramatically improve their physical capacity.

    Which person had the better outcome?

    The bathroom scale cannot answer that question.

    Chasing Only Weight

    The goal becomes making the number smaller regardless of what is being lost.

    Chasing Better Biology

    Reduce excess fat while protecting muscle, strength, performance, metabolic health, and function.

    What Does Muscle Have to Do With Longevity?

    Maybe the better question is: what does it not have to do with?

    Longevity conversations often become obsessed with molecules.

    NAD. Rapamycin. Metformin. Peptides. Supplements. Mitochondrial compounds. Senolytics.

    Some of that science is fascinating.

    I am interested in much of it too.

    But if we spend hours discussing experimental longevity therapies while someone is progressively losing muscle, getting weaker, becoming insulin resistant, and losing the ability to move independently, we may be missing the obvious.

    Living longer matters. Being capable enough to enjoy those years matters too.

    Medications and Peptides Can Be Levers

    But they are not the infrastructure

    This is where my view of personalized wellness comes in.

    A medication may help someone lose excess body fat.

    A recovery strategy may help someone tolerate rehabilitation.

    A hormone may need to be corrected when a true deficiency exists.

    A peptide or emerging therapy may someday prove useful for a specific biological pathway.

    Those can all be levers.

    But those levers should ideally help someone build a stronger physiological system.

    Muscle Is Infrastructure

    Drugs, supplements, peptides, nutrition strategies, and recovery tools can influence individual pathways.

    Muscle gives you metabolic capacity, physical strength, mitochondrial machinery, functional reserve, and the ability to actually interact with the world around you.

    Build the infrastructure first. Then decide which levers are worth pulling.

    The Goal Is Not to Become a Bodybuilder

    The goal is to remain capable

    You do not need enormous arms.

    You do not need visible abs.

    You do not need to deadlift 500 pounds.

    You need enough muscle and strength to continue doing the things that make your life yours.

    Carry the luggage.

    Pick up your grandkids.

    Get off the floor.

    Work in the yard.

    Recover from surgery.

    Take the stairs.

    Travel.

    Play.

    Live independently.

    Longevity without function is an incomplete goal.

    So yes, I am interested in the future of longevity medicine.

    I am interested in mitochondria, metabolic therapies, peptides, hormones, medications, and emerging science.

    But while we wait for the next breakthrough molecule, we already know something remarkably powerful:

    Stronger people tend to be more resilient people.

    And muscle is one of the few biological assets you can intentionally spend decades building.

    Build Muscle Before You Need It

    You may not know when illness, injury, surgery, aging, or inactivity will make a withdrawal from your physical reserve.

    Muscle is your metabolic savings account. Start making deposits.

    About the Author

    Personalized wellness starts by understanding the whole system

    Drew Kirkley, MSN, APRN, AGNP-C

    Adult-Gerontology Nurse Practitioner • University Nursing Professor • Founder of KirkleyCare

    Drew Kirkley’s approach to wellness focuses on helping people understand how metabolism, muscle, sleep, hormones, mitochondrial health, nutrition, recovery, and other systems interact—and identifying practical levers that may help them reach their individual health goals.

    Selected Scientific References

    Human research supporting the concepts discussed in this article
    Leong DP, et al. The Lancet. 2015.
    PURE study evaluating grip strength as a predictor of cardiovascular events and mortality.
    View on PubMed →
    Steensberg A, et al. Journal of Physiology. 2000.
    Human research demonstrating production and release of interleukin-6 from contracting skeletal muscle.
    View on PubMed →
    Helge JW, et al. Journal of Physiology. 2003.
    Human research evaluating exercise intensity, skeletal-muscle glucose uptake, and IL-6 release.
    View on PubMed →
    Davidson LE, et al. Archives of Internal Medicine. 2009.
    Randomized controlled trial evaluating resistance and aerobic exercise, insulin resistance, and functional limitation in older adults.
    View on PubMed →
    Watson SL, et al. Journal of Bone and Mineral Research. 2018.
    LIFTMOR randomized trial of supervised high-intensity resistance and impact training in postmenopausal women with low bone mass.
    View on PubMed →
    Wyckelsma VL, et al. Journal of Physiology. 2017.
    Skeletal-muscle mitochondrial content and adaptations following high-intensity exercise training in older adults.
    View on PubMed →
    Flack KD, et al. Physiological Reports. 2016.
    Randomized resistance-training study examining skeletal-muscle oxidative capacity in older adults.
    View on PubMed →
    Kortebein P, et al. 2007–2008.
    Human experimental bed-rest research examining rapid changes in skeletal muscle and physical function during ten days of complete inactivity in older adults.
    Skeletal Muscle Study →    Functional Study →
    Wyckelsma / Bed-Rest Mitochondrial Research.
    Human research demonstrating impaired skeletal-muscle energetics and mitochondrial function following ten days of bed rest in older adults.
    View on PubMed →
    Langer HT, et al. Cell Reports Medicine. 2026.
    Human and preclinical research examining body composition, muscle mass, strength, and physical function during GLP-1-based weight loss.
    View on PubMed →
    Alissou M, et al. Diabetes, Obesity and Metabolism. 2026.
    Prospective study evaluating semaglutide, fat mass, lean mass, muscle function, and resting energy expenditure.
    View on PubMed →
    Dideriksen KJ, et al. 2011.
    Randomized human study examining resistance exercise, protein ingestion, and muscle protein synthesis in older adults.
    View on PubMed →
    Educational Disclaimer: The title “The Most Underrated Longevity Drug Is Muscle” is a metaphor. Skeletal muscle is tissue, not a pharmaceutical drug. This article is intended for general health education and is not individualized medical, nutrition, or exercise advice. Exercise and nutritional needs differ according to age, medical history, medications, physical limitations, kidney function, bone health, injury history, and other factors. Individuals with significant medical conditions or physical limitations should discuss appropriate exercise and nutrition strategies with qualified health professionals.